A Form 4 filed on September 22, 2026 reports that J. Erik Fyrwald, a director of Eli Lilly & Co (NYSE:LLY), acquired 8.513 shares of common stock on September 21, 2026 under the company's Directors' Deferral Plan.

Key Highlights

  • Reporting person: J. Erik Fyrwald, director of Eli Lilly & Co
  • Transaction date: September 21, 2026
  • Shares acquired: 8.513 shares of common stock, transaction code "A" (acquired)
  • Price per share: $1,164.89
  • Beneficial ownership following transaction: 75,536.1308 shares, held directly
  • Deferral election: Shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan, to be settled in common stock following separation from service

Fyrwald Defers Director Compensation into Eli Lilly Stock Units

According to the filing, J. Erik Fyrwald, who serves as a director of Eli Lilly & Co (NYSE:LLY), acquired 8.513 shares of the company's common stock on September 21, 2026 at a price of $1,164.89 per share. The transaction was coded "A," indicating an acquisition, and the shares are held directly by the reporting person.

The filing includes a footnote explaining the nature of the acquisition: "At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service." As a result, the shares represent deferred compensation rather than an open-market purchase.

Following this transaction, Fyrwald's direct beneficial ownership stands at 75,536.1308 shares of Eli Lilly common stock, according to the filing. The Form 4 was signed by Christopher Anderson on behalf of J. Erik Fyrwald pursuant to an authorization on file, and was filed with the SEC on September 22, 2026. No derivative securities were reported in Table II of the filing.

What Was Disclosed

The filing discloses a single acquisition of 8.513 Eli Lilly common stock shares by director J. Erik Fyrwald on September 21, 2026, at $1,164.89 per share, deferred as stock units under the Lilly Directors' Deferral Plan, bringing his total direct beneficial ownership to 75,536.1308 shares.